Recent developments include multiple analyst coverage initiations with positive recommendations, a significant public offering, and leadership changes, reflecting active market engagement and corporate developments.

• Truist Securities initiated coverage of Inventiva S.A. with a Buy recommendation in March 2026 [N1].
• Barclays initiated coverage with an Overweight recommendation in January 2026 [N4].
• Leerink Partners initiated coverage with an Outperform recommendation in January 2026 [N6].
• Guggenheim maintained a Buy recommendation in November 2025 [N8].
• Inventiva completed an upsized public offering of about $150 million ADS in November 2025 [N8].
• Andrew Obenshain was named CEO in October 2025 [N8].
• Canaccord Genuity maintained a Buy recommendation in October 2025 [N8].
• Multiple analyst reports in early 2026 discuss potential upside and momentum for Inventiva [N2, N3, N5, N7].

Inventiva's lead candidate lanifibranor is in a pivotal Phase III trial with Fast Track Designation, supported by a broad patent portfolio and strategic collaborations in key territories. Positive clinical trial results and regulatory approvals could enable the company to address a significant unmet medical need in MASH, a disease with limited approved therapies. The company's focused pipeline and strengthened financial position following recent capital raises support continued development and potential commercialization efforts. Multiple analyst coverage initiations and positive market interest reflect recognition of the company's potential value.

Inventiva faces risks typical of clinical-stage biopharmaceutical companies, including the possibility that lanifibranor may not demonstrate sufficient safety or efficacy in ongoing trials, or may not receive regulatory approval. Manufacturing scale-up challenges and reliance on third-party contract manufacturers could delay development or commercialization. The company has incurred significant operating losses and may require additional financing, which could dilute shareholders or constrain operations. Competition from other companies with approved or emerging therapies for MASH may limit market opportunity. Regulatory, intellectual property, and commercial execution risks remain significant.

Inventiva's moat is primarily based on its proprietary pan-PPAR agonist lanifibranor, protected by a broad and extensive patent portfolio including multiple U.S. and international patents covering composition, methods of use, and formulations. The company's strategic collaborations with regional partners CTTQ and Hepalys provide localized development and commercialization capabilities, potentially enhancing market access. The clinical-stage status and Fast Track Designation by the FDA for lanifibranor add regulatory advantages. However, the biopharmaceutical industry is highly competitive with numerous companies developing therapies for MASH, and the company's moat depends on successful clinical development, regulatory approval, and market acceptance of lanifibranor.

• Clinical and Regulatory Risk: Lanifibranor is in late-stage clinical development but has not yet received regulatory approval. Failure to demonstrate safety and efficacy or to obtain regulatory approvals would materially impact the company's prospects.
• Manufacturing and Supply Risk: Reliance on contract manufacturing organizations requires successful scale-up and supply chain management. Delays or failures in manufacturing could disrupt clinical trials or commercialization.
• Financial Risk: The company has incurred significant losses and may require additional capital to fund operations. Insufficient funding could delay development or commercialization activities.
• Competition Risk: The MASH treatment landscape is competitive with multiple companies developing therapies. Competitors with approved products or superior efficacy could limit market penetration.
• Intellectual Property Risk: While Inventiva holds extensive patents, challenges to patent validity or infringement could reduce competitive advantage.

• Inventiva S.A. is a clinical-stage biopharmaceutical company focused on oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH).
• The lead product candidate is lanifibranor, a novel pan-PPAR agonist, currently in a pivotal Phase III clinical trial (NATiV3) for adult patients with MASH.
• Lanifibranor has received Fast Track Designation from the FDA for treatment of MASH.
• The NATiV3 Phase III trial completed patient randomization in April 2025, with topline results targeted for Q4 2026.
• Lanifibranor is being developed in collaboration with CTTQ for China and Hepalys for the Hepalys Territory, with Hepalys conducting and financing development trials in their territory.
• Hepalys conducted a positive Phase 1 trial of lanifibranor in Japan in 2025, supporting a planned pivotal trial in the Hepalys Territory after NATiV3 results.
• Inventiva owns a broad intellectual property portfolio for lanifibranor, including 7 issued U.S. patents and approximately 430 patents and applications worldwide as of March 2026.
• The company relies on contract manufacturing organizations (CMOs) for production of lanifibranor under cGMP regulations, with plans to scale production for clinical and potential commercial supply.
• The FDA approval process for lanifibranor involves multiple phases of clinical trials, regulatory submissions, and inspections, with no guarantee of approval.
• Inventiva has incurred significant operating losses since inception and finances operations through capital raises, debt, collaborations, and tax credits.
• As of June 30, 2025, Inventiva had cash and cash equivalents of €122.1 million and current assets of €172.8 million, with current liabilities of €58.5 million, resulting in a current ratio of 2.96 and cash ratio of 2.09.
• Revenue for the six months ended June 30, 2025 was €4.45 million, primarily from milestone payments under the CTTQ License Agreement.
• The company reported a basic and diluted loss per share of €1.62 for the six months ended June 30, 2025.
• Inventiva implemented a 2025 Pipeline Prioritization Plan to focus exclusively on lanifibranor development, terminating other programs.
• General and administrative expenses increased significantly in 2025 due to personnel costs and share-based compensation related to CEO transition and workforce reduction.
• Marketing and business development expenses increased in 2025, reflecting increased commercial development activities.
• Inventiva has contractual obligations including bank borrowings, royalty certificates, leases, and purchase obligations related to CRO/CMO agreements.
• The company estimates cash resources sufficient to finance operations until mid-Q1 2027, with potential extension if certain warrants are exercised.
• Multiple recent analyst firms have initiated or maintained coverage with positive recommendations and price targets, reflecting market interest.
• Recent news includes a public offering of about $150 million ADS and CEO appointment of Andrew Obenshain.
• Inventiva's business model centers on advancing lanifibranor through clinical development, regulatory approval, and potential commercialization, supported by strategic collaborations and intellectual property protection.